Subcutaneous Immunotherapy of Birch for Rosacea Fruit Allergy

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K14026
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 08030:Family and consumer sciences, and culture and living-related
• Research Institution: Kanagawa Children's Medical Center (Clinical Research Institute)
• Principal Investigator: Tsumagari Shuntaro 地方独立行政法人神奈川県立病院機構神奈川県立こども医療センター(臨床研究所), 臨床研究所, 医師 (90836545)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 食物アレルギー / 果物アレルギー / 末梢血好塩基球活性化 / アレルゲン免疫療法

Outline of Final Research Achievements

In recent years, the incidence of oral allergy syndrome associated with the ingestion of rosaceous fruits such as apples, peaches, and kiwis has increased. These fruit allergies are IgE-mediated immediate-type food allergic reactions, in which the ingestion of fruits that are cross-antigenic to pollen after the onset of pollen allergy symptoms causes allergic reactions localized to the oral cavity. Rosacea fruits have been reported to be cross-reactivities with birch pollen, mainly with the component Bet v 1.
In the present study, we show that subcutaneous injection immunotherapy with birch pollen reduces peripheral blood basophil activation to birch pollen and Bet v 1 in patients who develop fruit allergy.

Free Research Field

食物アレルギー

Academic Significance and Societal Importance of the Research Achievements

これまで治療効果が明確でなかった果物アレルギーに対するシラカンバ花粉皮下注射免疫療法の治療効果を末梢血好塩基球活性化検査で示すことが出来、早期から治療効果を提示することができるようになった。